We fund organizations and projects which disrupt our current behavioral health space and create impact at the individual, organizational, and societal levels.
Our annual $25,000 prize is awarded to a cutting-edge idea that holds the potential to catalyze progress in behavioral health.
Our participatory grantmaking alters the traditional process of philanthropic giving by empowering service providers and community-based organizations to define the strategy around a specific issue area or population.
We provide funds at below-market interest rates that can be particularly useful to start, grow, or sustain a program, or when results cannot be achieved with grant dollars alone.
Contact Ami about the RISE Partnership.
Contact Alyson about grantmaking, program related investments, and the paper series.
Contact Samantha about program planning and evaluation consulting services.
Contact Caitlin about the Community Fund for Immigrant Wellness, the Annual Innovation Award, and trauma-informed programming.
Contact Joy with any questions about the Scattergood Foundation.
Contact Joe about partnership opportunities, thought leadership, and the Foundation’s property.
Psychoactive medications are the most expensive and fastest-growing class of pharmaceutical agents for children. The cost, side effects, and unprecedented growth rate at which these drugs are prescribed has raised alarms from health care clinicians, patient advocates, and agencies about the appropriateness of how these drugs are distributed to parents and their children.
The authors of a newly released paper in the Think Bigger Do Good Policy Series reviews the current prescribing of three classes of psychoactive drug (stimulants, antidepressants, and antipsychotics) and efforts to improve pediatric prescribing of these.
Authors, Kelly J. Kelleher, M.D., M.P.H., David Rubin, M.D., M.S.C.E., Kimberly Hoagwood, Ph.D., call for system level interventions and in federal and state policies to address this growing utilization of psychoactive medications. Their recommendations include:
-Standardization of treatment protocols and increased emphasis on the value of shared decision making between providers and caregivers.
-The creation of and further implementation of state or insurance company monitoring programs that review prescribing data both retrospectively or prospectively and, in some cases, have peer to peer monitoring by prescribers.
-Greater transparency in prices and incentives among insurers, public agencies, and pharmacy benefit managers.
-Requiring direct negotiations between state Medicaid agencies and drug manufacturers to reduce costs and inappropriate incentives.
-Payment for outcomes related to costs through the larger adoption of value-based purchasing and specifically value-based payment for medications.
We ask that you send the paper to your local, state, and/or federal policy and decision-makers, to advocate for policy reforms and restructured financing models to increase access to integrated behavioral health services.